182 related articles for article (PubMed ID: 16797284)
21. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
Wang J; Zeevi A; McCurry K; Schuetz E; Zheng H; Iacono A; McDade K; Zaldonis D; Webber S; Watanabe RM; Burckart GJ
Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus.
Vafadari R; Bouamar R; Hesselink DA; Kraaijeveld R; van Schaik RH; Weimar W; Baan CC; van Gelder T
Ther Drug Monit; 2013 Aug; 35(4):459-65. PubMed ID: 23743668
[TBL] [Abstract][Full Text] [Related]
23. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
26. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
27. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
28. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Tanaka K; Uemoto S; Inui K
J Pharmacol Exp Ther; 2008 May; 325(2):610-6. PubMed ID: 18252812
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients.
Li Y; Hu X; Cai B; Chen J; Bai Y; Tang J; Liao Y; Wang L
Transpl Immunol; 2012 Aug; 27(1):12-8. PubMed ID: 22504573
[TBL] [Abstract][Full Text] [Related]
30. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
[TBL] [Abstract][Full Text] [Related]
31. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.
Foote CJ; Greer W; Kiberd BA; Fraser A; Lawen J; Nashan B; Belitsky P
Transplant Proc; 2006 Nov; 38(9):2847-9. PubMed ID: 17112845
[TBL] [Abstract][Full Text] [Related]
32. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O
Transplantation; 2008 Nov; 86(9):1206-13. PubMed ID: 19005401
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
34. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
Anglicheau D; Verstuyft C; Laurent-Puig P; Becquemont L; Schlageter MH; Cassinat B; Beaune P; Legendre C; Thervet E
J Am Soc Nephrol; 2003 Jul; 14(7):1889-96. PubMed ID: 12819250
[TBL] [Abstract][Full Text] [Related]
35. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.
Chakkera HA; Chang YH; Bodner JK; Behmen S; Heilman RL; Reddy KS; Mulligan DC; Moss AA; Khamash H; Katariya N; Hewitt WR; Pitta TL; Frassetto LA
Transplant Proc; 2013; 45(1):137-41. PubMed ID: 23375287
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth.
Drozdzik M; Mysliwiec K; Lewinska-Chelstowska M; Banach J; Drozdzik A; Grabarek J
J Clin Periodontol; 2004 Sep; 31(9):758-63. PubMed ID: 15312098
[TBL] [Abstract][Full Text] [Related]
37. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
38. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.
Foote CJ; Greer W; Kiberd B; Fraser A; Lawen J; Nashan B; Belitsky P
Transplantation; 2007 May; 83(10):1380-4. PubMed ID: 17519790
[TBL] [Abstract][Full Text] [Related]
40. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.
Yan L; Li Y; Tang JT; An YF; Wang LL; Shi YY
Pharmacogenomics; 2016 Feb; 17(3):249-57. PubMed ID: 26784512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
